Literature DB >> 17001315

p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A.

K Rother1, R Kirschner, K Sänger, L Böhlig, J Mössner, K Engeland.   

Abstract

Overexpression of Cdc25A phosphatase is often observed in cancer and results in poor prognosis. Cdc25A mainly dephosphorylates and thereby activates Cyclin-dependent kinase 2 and thus induces progression in the cell cycle from G(1) to S phase. Here, we demonstrate that the tumor suppressor p53 downregulates expression from the Cdc25A gene. In a p53-inducible cell system, Cdc25A expression on the mRNA and protein level is downregulated upon p53 expression. Promoter-reporter assays show that this regulation is dependent on the Cdc25A promoter. Mutant p53 fails to reduce Cdc25A transcription. In contrast to p53, neither p63 nor p73 can repress Cdc25A transcription. The Cdc25A promoter displays no p53 binding site, and p53 does not bind directly to the promoter DNA as shown by chromatin immunoprecipitation assays. Previously, the contribution of p53 to G(1)/S arrest has been mostly linked to activating the expression of the Cdk inhibitor p21(WAF1/CIP1). By downregulating Cdc25A expression, p53 may impair transition from G(1) to S phase independently of p21(WAF1/CIP1). Therefore, the data suggest that, as long as p53 is intact, Cdc25A transcriptional downregulation might play a role in cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001315     DOI: 10.1038/sj.onc.1209989

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response.

Authors:  Joris Pothof; Nicole S Verkaik; Wilfred van IJcken; Erik A C Wiemer; Van T B Ta; Gijsbertus T J van der Horst; Nicolaas G J Jaspers; Dik C van Gent; Jan H J Hoeijmakers; Stephan P Persengiev
Journal:  EMBO J       Date:  2009-06-18       Impact factor: 11.598

2.  Multimodal control of Cdc25A by nitrosative stress.

Authors:  Robert J Tomko; John S Lazo
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 3.  The role of Cdc25A in the regulation of cell proliferation and apoptosis.

Authors:  Tao Shen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2012-07       Impact factor: 2.505

4.  Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma.

Authors:  Adil Anwar; David A Norris; Mayumi Fujita
Journal:  Arch Biochem Biophys       Date:  2010-12-15       Impact factor: 4.013

5.  The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.

Authors:  Guangan He; Jian Kuang; Abdul R Khokhar; Zahid H Siddik
Journal:  Gynecol Oncol       Date:  2011-05-18       Impact factor: 5.482

Review 6.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

Review 7.  Interplay between HMGA and TP53 in cell cycle control along tumor progression.

Authors:  Nathalia Meireles Da Costa; Antonio Palumbo; Marco De Martino; Alfredo Fusco; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti
Journal:  Cell Mol Life Sci       Date:  2020-09-12       Impact factor: 9.261

8.  Loss of cyclin-dependent kinase 2 (CDK2) inhibitory phosphorylation in a CDK2AF knock-in mouse causes misregulation of DNA replication and centrosome duplication.

Authors:  Hui Zhao; Xueyan Chen; Mark Gurian-West; James M Roberts
Journal:  Mol Cell Biol       Date:  2012-02-13       Impact factor: 4.272

9.  A ceRNA analysis on LMNA gene focusing on the Hutchinson-Gilford progeria syndrome.

Authors:  Walter Arancio; Carla Giordano; Giuseppe Pizzolanti
Journal:  J Clin Bioinforma       Date:  2013-01-14

10.  p53 can repress transcription of cell cycle genes through a p21(WAF1/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements.

Authors:  Marianne Quaas; Gerd A Müller; Kurt Engeland
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.